THE INFLUENCE OF PROGENITOR NEUROCELLS SUPERNATANT ON THE LYMPHOCYTES CYTOTOXIC FUNCTION IN RATS WITH GLIOMA
L.D. Liubich, N.I. Lisyany
SI «A.P. Romodanov Institute of Neurosurgery NAMS of
The impact of rat neurogenic progenitor cells supernatant
(RPNS) on the cytotoxic function of lymphocytes in rats under
conditions of physiological norm and experimentally modeled
tumor (brain glioma strain 101.8) was studied. The research
was carried out in animals with inoculated tumor without
RPNS injection and with different regimes of RPNS injection
(thrice repeated from 5th to 10th day after glioma inoculation
as well as 1 week and 1 month before tumor inoculation). Comparison
groups included rats without glioma who triple injected
with RPNS; and intact animals (control). RPNS was received
from suspension of neurogenic progenitor cells (NPC) of rat
brain on 14th day of gestation and injected intraperitoneally
(0,12 mg per animal). Cytotoxic function of lymphocytes of
experimental rats was evaluated in MTT-colorimetric test with
allogeneic glioma cells. RPNS administration increased the
cytotoxic activity of lymphocytes in vitro tests with allogeneic
tumor cells in intact animals (to 37-38%) as well as in rats
with glioma (to 11-22%). Under the RPNS influence the life
expectancy and median survival of tumor-bearing animals
increased (an average of 3-4 days). RPNS input modes such
as triple injection from 5th to 10th day after glioma inoculation
and 1 week before inoculation were the most effective. Thus,
indirect tumor-inhibiting effect under intraperitoneal RPNS
administration in rats with glioma is demonstrated, which is
obviously due to increased efficiency of cytotoxic function
of immune cells of animals with inoculated tumor under the
influence of the factors produced by NPC.
lymphocytes cytotoxic function; glioma 101.8; progenitor neurocells supernatant.
- Lisyany NI. Immunology and immunotherapy of malignant brain gliomas. Kiev: Interservice; 2011. [Russian].
- Ghosh A, Bhattacharya M, Sarkar P, Acharya S, Chaudhury S. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment. Indian J Exp Biol. 2010; 48(9): 879-88.
- Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH. Profiling of CD4+, CD8+, and CD4+CD25+ CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006; 12(24): 7306-15.
- Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H. Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol. 2005; 64 (10): 891-901.
- Nano R, Capelli E, Facoetti A, Benericetti E. Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res.2009;29:2461-6.
- Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 2007; 114 (2): 111-9.
- Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neuroimmunol. 2010; 220 (1-2): 131-5.
- Kren L, Slaby O, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Lakomy R, Vanhara P. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance. Neuropathology. 2011; (2): 129-34.
- Achanta P, Sedora Roman NI, Qui-ones-Hinojosa A. Gliomagenesis and the use of neural stem cells in brain tumor treatment. Anticancer Agents Med Chem. 2010;10 (2): 121-30.
- Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol Med. 2013; 19 (5): 281-91.
- Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011; 7(1): 130-40.
- Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol. 2012; 797: 97-109.
- Staflin K, Lindvall M, Zuchner T, Lundberg C. Instructive cross-talk between neural progenitor cells and gliomas. J Neurosci.Res. 2007; 85(10): 2147-59.
- Halanskij AS, Kondakova LI, Avcyn AP. New transplantable rat brain gliomas. Voprosy nejrohirurgii.1995; (2): 23-5. [Russian].
- Liubich LD, Lisyany NI, inventor; SI "Institute of neurosurgery n.acad.A.Romodanov NAMS of Ukraine", assignee. Method of study of allocytotoxic activity of immune cells. Ukraine patent UA 75059. 2012 Nov 11. [Ukrainian].
- Chen HC, Ma HI, Sytwu HK, Wang HW, Chen CC, Liu SC, Chen CH, Chen HK, Wang CH. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. J Neurosci Res. 2010; 88(15): 3308-18.
- Klassen HJ, Imfeld KL, Kirov II, Tai L, Gage FH, Young MJ, Berman MA. Expression of cytokines by multipotent neural progenitor cells. Cytokine. 2003; 22(3-4): 101-6.
- Liu J, Götherström C, Forsberg M, Samuelsson EB, Wu J, Calzarossa C, Hovatta O, Sundström E, Åkesson E. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013; 10(3): 325-37.
- Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 2002; 62(20): 5657-63.
- Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol. 2004; 23(6): 381-9.
- Yuan X, Hu J, Belladonna ML, Black KL, Yu JS. Interleukin-23-expressing bone-marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006; 66(5): 2630-8.
- Miwa N., Mizuno S., Suitani Y. Tumor growth-inhibitory glycoprotein secreted from the mouse brain at terminal stage of the ontogeny: molecular homogeneity and requirement of the retained protein conformation for exhibition of the cytotoxic action. Biochim.Biophys. Acta. 1990; 1034(3): 309-17